

Special Issue

Molecular Mechanisms of Cancer Drug Resistance

Message from the Guest Editors

Drug resistance, existing before treatment (intrinsic) or generated after therapy (acquired), is responsible for most cancer relapses and associated deaths. Drug resistance arises not only with classical chemotherapy but also, more recently, with tumor-target and immunotarget therapies. The heterogeneity among patients, tumors, and cancer microenvironments and the adaptability of cancer cells in evading therapies make it more challenging to address drug resistance. Although our knowledge in understanding drug resistance over the past decade has definitively grown, gaps remain in identifying the biological, pharmacodynamic, and pharmacokinetic causes behind drug resistance and designing cancer therapies and schedules to overcome it. This Special Issue aims to respond to this clinical need, with studies leading to the discovery of significant biomarkers for the development of a new combination of anticancer treatments that prevent or overcome potential resistance. Furthermore, emphasizing the pharmacological action of anticancer drugs may help to challenge complexity by better predicting optimal strategies.

Guest Editors

Dr. Maria Grazia Cerrito

Department of Medicine and Surgery, University of Milano-Bicocca, Via Cadore 48, 20900 Monza, Italy

Prof. Dr. Guido Bocci

Department of Clinical and Experimental Medicine School of Medicine, University of Pisa, Via Roma 55, 56126 Pisa, Italy

Deadline for manuscript submissions

closed (31 January 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/107842

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).